Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23096828 | 0.84 | TDP1 (0.45) | KMT2ASMN1; SMN2TDP1CYP1A2MEN1 | |
| SCHEMBL5530068 | 0.81 | ATM (0.60) | KMT2ASMN1; SMN2TDP1MEN1ALDH1A1 | |
| SCHEMBL3242393 | 0.79 | SMN1; SMN2 (0.51) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL3949996 | 0.79 | CYP1A2 (0.48) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL3498067 | 0.79 | ATM (0.58) | KMT2ASMN1; SMN2TDP1CYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL27078195 | 0.78 | SMN1; SMN2 (0.50) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL6044018 | 0.77 | TDP1 (0.50) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL6044015 | 0.77 | TDP1 (0.50) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL805507 | 0.77 | GNAI3 (0.50) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL12443868 | 0.76 | DDB1 (0.44) | KMT2ASMN1; SMN2TDP1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200362339-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-19 | — | — | US | disclosed |
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
| CN-1186434-A | Pharmaceutical composition containing protease inhibitor and monoglyceride | HOFFMANN LA ROCHE (US) | 1998-07-01 | — | — | CN | disclosed |
| CN-1089606-A | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1994-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | KMT2A 3789/4885HTT 3305/4885SMN1; SMN2 4824/4885 |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | KMT2A 1766/4885HTT 3801/4885SMN1; SMN2 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.